More Research

Hutchison China MediTech

$110m raised through ADS public offer
Lighthouse | 23 Jan 2020

Hutchison China MediTech

SANET-p trial stopped early for efficacy
Lighthouse | 21 Jan 2020

Hutchison China MediTech

Elunate (fruquintinib) secures China NRDL listing
Lighthouse | 29 Nov 2019

Hutchison China MediTech

Acceptance of surufatintib China NDA in epNET
Lighthouse | 12 Nov 2019

Hutchison China MediTech

ESMO 2019: surufatinib epNET PFS benefit confirmed
Update | 03 Oct 2019

Hutchison China MediTech

WCLC 2019: detailed FALUCA data disclosed
Update | 11 Sep 2019

Hutchison China MediTech

Carrying momentum into H219
Update | 13 Aug 2019

Hutchison China MediTech

Secondary ADS offering trims CK Hutchison stake
Lighthouse | 28 Jun 2019

Hutchison China MediTech

Surufatinib on track for potential 2020 China approval
Update | 18 Jun 2019

Hutchison China MediTech

Impressive data means SANET-ep trial stopped early
Lighthouse | 14 Jun 2019

1 2 3 4
Return to HUTCHMED
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).